A comparison between standard triple therapy and sequential therapy on eradication of Helicobacter pylori in uremic patients: A randomized clinical trial


1 Department of Nephrology, Imam Khomeini Hospital; Department of Immunology, Biology Molecular and Cellular Research Center, Sari, Iran

2 Department of Gastroenterology, Mazandaran University of Medical Sciences, Sari, Iran

3 Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran

4 Department of Nephrology, Imam Khomeini Hospital, Sari, Iran

5 Department of Gastroenterology, Imam Khomeini Hospital, Sari, Iran

6 Department of Community Medicine, Mazandaran University of Medical Sciences, Sari, Iran


Background: The prevalence of peptic ulcer disease in hemodialysis dependent patients is higher than the general population. These patients are also more prone to upper gastrointestinal bleeding. The aim of this study was to compare the effects of a standard triple therapy with a sequential therapy on Helicobacter pylori eradication in azotemic and hemodialysis patients.
Materials and Methods: Forty nine hemodialysis and azotemic patients, naïve to H. pylori treatment, were randomized into two groups to receive either standard triple therapy (pantoprazole 40 mg, amoxicillin 500 mg and clarithromycin 250 mg twice a day for 14 days) or a sequential therapy (pantoprazole 40 mg for 10 days, amoxicillin 500 mg twice a day for the first 5 days and clarithromycin 250 mg + tinidazole 500 mg twice a day just during the second 5 days). H. pylori eradication was evaluated by fecal H. pylori antigen assessment 8 weeks after the treatment.
Results: Of 49 patients, 45 patients (21 in triple therapy group and 24 in the sequential group) completed the study. Based on intention to treat analysis, H. pylori eradication rates were 66.7% (95% confidence interval [CI]: 47.8-85.5%) in standard triple therapy group and 84% (95% CI: 69.6-98.3%) in sequential therapy group (P = 0.34). Per-protocol (PP) eradication rates were (95% CI: 76.2%. 6-89.3%) 54 and 87.5% (95% CI: 68.8-95.5%), respectively (P = 0.32).
Conclusion: According to Maastricht III consensus report, the results of our study showed that sequential therapy might be a better choice compared with the standard triple therapy in azotemic and hemodialysis patients Iran. We propose to assess the effects of shorter-duration sequential therapy (less than 10 days) for H. pylori eradication.


Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 2002;13 Suppl 1:S37-40.  Back to cited text no. 1
Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008;13 Suppl 1:35-40.  Back to cited text no. 2
Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol 1995;7:427-33.  Back to cited text no. 3
Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int 2009;75:96-103.  Back to cited text no. 4
Gioè FP, Cudia B, Romano G, Cocchiara G, Li Vecchi V, Gioè MA, et al. Role and clinical importance of Helicobacter pylori infection in hemodialysis patients. G Chir 2008;29:81-4.  Back to cited text no. 5
Suzuki H, Saito Y, Hibi T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: Updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 2009;3:81-7.  Back to cited text no. 6
Lentine KL, Parsonnet J, Taylor I, Wrone EM, Lafayette RA. Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. Clin Exp Nephrol 2006;10:55-62.  Back to cited text no. 7
Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Muñoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;19:617-29.  Back to cited text no. 8
Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, et al. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc 2007;39:1003-7.  Back to cited text no. 9
Fábián G, Szigeti N, Kovács T, Nagy J. An unusual multiplex cause of severe gastrointestinal bleeding in a haemodialysed patient. Nephrol Dial Transplant 2000;15:1869-71.  Back to cited text no. 10
Sugimoto M, Yamaoka Y. Review of Helicobacter pylori infection and chronic renal failure. Ther Apher Dial 2011;15:1-9.  Back to cited text no. 11
Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III consensus report. Gut 2007;56:772-81.  Back to cited text no. 12
Nam TM, Lee DH, Kang KP, Lee JH, Chung JI, Choi HC, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc 2008;36:200-5.  Back to cited text no. 13
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.  Back to cited text no. 14
Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79.  Back to cited text no. 15
Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: A meta-analysis. J Clin Pharm Ther 2009;34:41-53.  Back to cited text no. 16
Jafri NS, Hornung CA, Howden CW. Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.  Back to cited text no. 17
Sánchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008;103:2220-3.  Back to cited text no. 18
Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: A randomized clinical trial. Helicobacter 2012;17:43-8.  Back to cited text no. 19
Cocchiara G, Romano M, Buscemi G, Maione C, Maniaci S, Romano G. Advantage of eradication therapy for Helicobacter pylori before kidney transplantation in uremic patients. Transplant Proc 2007;39:3041-3.  Back to cited text no. 20
Itatsu T, Miwa H, Nagahara A, Kubota M, Miyazaki A, Sato N, et al. Eradication of Helicobacter pylori in hemodialysis patients. Ren Fail 2007;29:97-102.  Back to cited text no. 21
Ecclissato C, Marchioretto MA, Mendonça S, Godoy AP, Guersoni RA, Deguer M, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002;7:53-9.  Back to cited text no. 22
Wang YL, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. Am J Kidney Dis 2001;38:98-103.  Back to cited text no. 23
Tsukada K, Miyazaki T, Katoh H, Masuda N, Ojima H, Fukai Y, et al. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients. Scand J Gastroenterol 2002;37:1265-8.  Back to cited text no. 24
Sezer S, Ibiþ A, Ozdemir BH, Ozdemir FN, Külah E, Boyacioðlu S, et al . Association of Helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc 2004;36:47-9.  Back to cited text no. 25
Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, et alHelicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. Clin Exp Nephrol 2010;14:469-73.  Back to cited text no. 26
Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ 2002;166:473-7.  Back to cited text no. 27
Fabrizi F, Martin P. Helicobacter pylori infection in patients with end-stage renal disease. Int J Artif Organs 2000;23:157-64.  Back to cited text no. 28
De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: A prospective, randomised study. Dig Liver Dis 2004;36:322-6.  Back to cited text no. 29
Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.  Back to cited text no. 30
De Francesco V, Della Valle N, Stoppino V, Amoruso A, Muscatiello N, Panella C, et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2004;19:993-8.  Back to cited text no. 31
Seyyedmajidi M, Falaknazi K, Mirsattari D, Zojaji H, Roshani M, Lahmi F, et al. Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. Arab J Gastroenterol 2011;12:150-3.  Back to cited text no. 32
Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.  Back to cited text no. 33